Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

Fig. 3

Knockdown of Src sensitizes prostate cancer cells to CYT997. a The shRNAs against Src (shSrc-1, shSrc-2) were used to deplete Src expression in DU145 and PC3 cells. The shRNA against GFP (shGFP) was used as a negative control. After transfection and infection, the puromycin-resistant stable cells were verified for knockdown by Western blot. b, c Src knockdown and control cells were treated with 60 nM CYT997. Cell proliferation was determined at 48 h after treatment by MTS assays (b), and cell invasion was determined at 24 h after treatment by Matrigel-coated modified Boyden chambers (c). *p < 0.05; **p < 0.01

Back to article page